Teladoc Health reported its second quarter 2024 financial results, revealing a revenue of $642.4 million, a 2% decline year-over-year. The company posted a significant net loss of $837.7 million, or $4.92 per share, which included a goodwill impairment charge of $790 million, equating to $4.64 per share. Adjusted EBITDA for the quarter was $89.5 million, exceeding estimates of $74.2 million and marking a 24% increase from the previous year. Following the earnings report, Teladoc's shares fell by 12.5% in after-hours trading, and the company withdrew its annual and long-term guidance due to ongoing challenges, particularly in its BetterHelp segment. The CEO noted continued headwinds impacting overall results, contributing to a further decline in share value, which closed down more than 8% on the following day.